89Zr-TLX250 PET/CT
Phase 3Recruiting 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clear Cell Renal Cell Carcinoma
Conditions
Clear Cell Renal Cell Carcinoma
Trial Timeline
Nov 6, 2024 → Jun 30, 2026
NCT ID
NCT06750419About 89Zr-TLX250 PET/CT
89Zr-TLX250 PET/CT is a phase 3 stage product being developed by Telix Pharmaceuticals for Clear Cell Renal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06750419. Target conditions include Clear Cell Renal Cell Carcinoma.
What happened to similar drugs?
3 of 12 similar drugs in Clear Cell Renal Cell Carcinoma were approved
Approved (3) Terminated (1) Active (8)
✅nebulized albuterol (2.5 mg/3ml/dose) + nebulized levalbuterol (1.25 mg/3ml/dose) + nebulized placebo (3ml/dose)Sumitomo PharmaApproved
Hype Score Breakdown
Clinical
17
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06750419 | Phase 3 | Recruiting |
Competing Products
20 competing products in Clear Cell Renal Cell Carcinoma